| 1379770-87-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• CAS: 1379770-87-2
• 化学式: Br*C₁₂H₁₂N₃
• 分子量: 278.151
• InChiKey: DQPJJMRUTLNFBJ-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -1.76
• 重原子数：
  16.0
• 可旋转键数：
  2.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  32.6
• 氢给体数：
  0.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  在 六氟磷酸钾 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 15.0h， 生成
  参考文献：
  名称：

  Silver(I)-N-heterocyclic carbene complexes of nitrile-functionalized imidazol-2-ylidene ligands as anticancer agents

  摘要：

  Reactions of symmetrically and non-symmetrically substituted nitrile-functionalized imidazolium salts (1-3) with silver(l) oxide in methanol at room temperature afforded complexes (4-6) of the type [NHC-Ag-NHC]PF6, (NHC: imidazol-2-ylidene). All reported compounds have been characterized by spectral (H-1, C-13 NMR and FTIR) and elemental analysis. The structure of bis-imidazolium salt 3 and silver complex 4 was unambiguously elucidated by the single-crystal X-ray diffraction method. The effect of substitutions on the anticancer activity of compounds 1-6 has been investigated by in vitro cytotoxicity studies against human colorectal (HCT 116) cancer cell line, using the MTT assay method. All three silver complexes (4-6) displayed promising anticancer activity with IC50 values of 6.0 +/- 0.2, 14.0 +/- 0.6 and 4.0 +/- 0.2 mu M, while imidazolium salts, 1-3, showed least (>200 mu M) to moderate (20.3 +/- 0.2 and 95.0 +/- 2 mu M) anticancer potential, respectively. Bis-imidazolium salt 3 and binuclear complex 6 displayed good activity against human breast (MCF-7) cancer line with IC50 values of 82.4 +/- 2.5 and 0.9 +/- 0.4 mu M, respectively. (C) 2014 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.inoche.2014.03.016
• 作为产物：
  描述：

  N-甲基咪唑 、 3-氰基苄基溴 以 1,4-二氧六环 为溶剂， 反应 20.0h， 生成
  参考文献：
  名称：

  Silver(I)-N-heterocyclic carbene complexes of nitrile-functionalized imidazol-2-ylidene ligands as anticancer agents

  摘要：

  Reactions of symmetrically and non-symmetrically substituted nitrile-functionalized imidazolium salts (1-3) with silver(l) oxide in methanol at room temperature afforded complexes (4-6) of the type [NHC-Ag-NHC]PF6, (NHC: imidazol-2-ylidene). All reported compounds have been characterized by spectral (H-1, C-13 NMR and FTIR) and elemental analysis. The structure of bis-imidazolium salt 3 and silver complex 4 was unambiguously elucidated by the single-crystal X-ray diffraction method. The effect of substitutions on the anticancer activity of compounds 1-6 has been investigated by in vitro cytotoxicity studies against human colorectal (HCT 116) cancer cell line, using the MTT assay method. All three silver complexes (4-6) displayed promising anticancer activity with IC50 values of 6.0 +/- 0.2, 14.0 +/- 0.6 and 4.0 +/- 0.2 mu M, while imidazolium salts, 1-3, showed least (>200 mu M) to moderate (20.3 +/- 0.2 and 95.0 +/- 2 mu M) anticancer potential, respectively. Bis-imidazolium salt 3 and binuclear complex 6 displayed good activity against human breast (MCF-7) cancer line with IC50 values of 82.4 +/- 2.5 and 0.9 +/- 0.4 mu M, respectively. (C) 2014 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.inoche.2014.03.016